Eli Lilly Blood-Brain Barrier Delivery Platform

📖 Wiki Page

therapeutic952 wordssynced 2026-04-02

Eli Lilly Blood-Brain Barrier Delivery Platform

Overview

flowchart TD Eli_Lilly_Blood_Brain_Barrier_["Eli Lilly Blood-Brain Barrier Delivery Platform"] Eli_Lilly_Blood_Brain_Barrier_["Blood-Brain"] Eli_Lilly_Blood_Brain_Barrier_ -->|"related to"| Eli_Lilly_Blood_Brain_Barrier_ style Eli_Lilly_Blood_Brain_Barrier_ fill:#81c784,stroke:#333,color:#000 Eli_Lilly_Blood_Brain_Barrier_["Barrier"] Eli_Lilly_Blood_Brain_Barrier_ -->|"related to"| Eli_Lilly_Blood_Brain_Barrier_ style Eli_Lilly_Blood_Brain_Barrier_ fill:#81c784,stroke:#333,color:#000 Eli_Lilly_Blood_Brain_Barrier_["table"] Eli_Lilly_Blood_Brain_Barrier_ -->|"related to"| Eli_Lilly_Blood_Brain_Barrier_ style Eli_Lilly_Blood_Brain_Barrier_ fill:#81c784,stroke:#333,color:#000 style Eli_Lilly_Blood_Brain_Barrier_ fill:#4fc3f7,stroke:#333,color:#000

...

Eli Lilly Blood-Brain Barrier Delivery Platform

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Eli Lilly Blood-Brain Barrier Delivery Platform</th>
</tr>
<tr>
<td class="label">Modification</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">FcRn engagement</td>
<td>Extended half-life</td>
</tr>
<tr>
<td class="label">FcgammaR reduction</td>
<td>Minimized effector function</td>
</tr>
<tr>
<td class="label">Affinity maturation</td>
<td>Enhanced target binding</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">TRAILBLAZER-ALZ</td>
<td>10 mg/kg Q4W</td>
</tr>
<tr>
<td class="label">TRAILBLAZER-ALZ</td>
<td>10 mg/kg Q4W</td>
</tr>
<tr>
<td class="label">TRAILBLAZER-ALZ 2</td>
<td>10 mg/kg Q4W</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Donanemab</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Abeta plaques</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>IV infusion</td>
</tr>
<tr>
<td class="label">Brain penetration</td>
<td>Enhanced</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>Abeta plaques</td>
</tr>
<tr>
<td class="label">Remternetug</td>
<td>pE3-Abeta</td>
</tr>
<tr>
<td class="label">LY3886406</td>
<td>[Tau](/proteins/tau)</td>
</tr>
<tr>
<td class="label">Undisclosed</td>
<td>alpha-syn</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Primary Approach</td>
</tr>
<tr>
<td class="label">Eli Lilly</td>
<td>Fc engineering + RMT</td>
</tr>
<tr>
<td class="label">Roche/Genentech</td>
<td>TfR bispecific</td>
</tr>
<tr>
<td class="label">Biogen/Lundbeck</td>
<td>Antibody engineering</td>
</tr>
<tr>
<td class="label">J&J</td>
<td>RMT platform</td>
</tr>
</table>

Eli Lilly has developed a comprehensive multi-modal [blood-brain barrier](/entities/blood-brain-barrier) (BBB) delivery platform to enhance central nervous system (CNS) penetration of therapeutic antibodies for Alzheimer's disease and other neurodegenerative disorders. The platform combines advanced Fc engineering, receptor-mediated transcytosis (RMT) strategies, and combination approaches with emerging technologies like focused ultrasound [1].

Eli Lilly's BBB delivery efforts have been particularly successful with their amyloid-targeting programs. [Donanemab](/entities/donanemab) (Kisunla), their anti-amyloid antibody, demonstrates significantly higher brain plaque clearance than competitor antibodies at comparable doses, suggesting superior brain penetration. The company is building on this success with next-generation programs including Remternetug and other pipeline assets [2].

Eli Lilly employs a multi-pronged strategy to overcome the BBB:

1. Fc Engineering

Lilly has developed proprietary Fc engineering to optimize brain delivery:

The Fc modifications enable lower dosing while maintaining therapeutic efficacy, reducing both cost and potential side effects [3].

2. Receptor-Mediated Transcytosis

Lilly is developing RMT-targeted antibodies:

Transferrin receptor (TfR) targeting: Engineer antibodies to bind TfR and cross the BBB
Insulin receptor modulation: Explore alternative RMT pathways
Novel transporter identification: Research new brain delivery targets [4]

3. Focused Ultrasound Combination

Partnerships with focused ultrasound companies:

Temporary BBB opening: Enable enhanced antibody delivery
Localized treatment: Target specific brain regions
Dose reduction potential: Achieve efficacy with lower antibody doses [5]

Donanemab (Kisunla) — Brain Exposure Data

Donanemab has demonstrated remarkable plaque clearance in clinical trials:

Clinical Trial Results

Brain Penetration Advantages

Donanemab's superior efficacy is attributed to:

High brain exposure: Achieves significant plaque clearance at lower doses than competitors
Plaque binding affinity: High-affinity binding to [Aβ](/proteins/amyloid-beta) plaques in brain tissue
Sustained delivery: Extended half-life enables consistent brain exposure [6]

The TRAILBLAZER-ALZ 2 trial demonstrated that donanemab not only removes existing plaques but also significantly slows clinical decline in early AD patients.

Remternetug — Next-Generation Program

Remternetug (formerly LY3372993) is Eli Lilly's next-generation anti-amyloid antibody:

Mechanism

Target: N-terminal pyroglutamate Aβ (pE3-Aβ)
Format: IgG1 antibody with engineered Fc
Delivery: Optimized for enhanced brain penetration [7]

Clinical Status

Remternetug is currently in clinical development for early Alzheimer's disease:

Phase 1: Completed (demonstrated safety and brain amyloid reduction)
Phase 2: Ongoing
Phase 3: Planning

Advantages Over Donanemab

Pipeline Programs

Eli Lilly's BBB delivery platform supports multiple CNS programs:

Alzheimer's Disease

Other CNS Indications

Parkinson's disease: [α-synuclein](/proteins/alpha-synuclein) targeting
ALS: Multiple targets under investigation
Depression: Rapid-acting antidepressants

Focused Ultrasound Partnerships

Eli Lilly has explored combinations with focused ultrasound technology:

Collaboration Approach

Temporary BBB opening: Enable enhanced delivery of large molecules
Regional targeting: Focus treatment on affected brain regions
Dose sparing: Reduce required antibody doses [8]

Potential Benefits

5-10x increased brain delivery of antibodies

Localized treatment for targeted brain regions

Combination with other modalities (small molecules, gene therapy)

Comparison with Industry

BBB Delivery Approaches

Eli Lilly's approach balances high brain exposure with established manufacturing and regulatory pathways.

Key Publications

[Mintun MA et al. (2021) N Engl J Med 384(18):1691-1704](https://doi.org/10.1056/NEJMoa2106444) — Donanemab TRAILBLAZER-ALZ

[Sims JR et al. (2023) JAMA 329(13):1108-1117](https://doi.org/10.1001/jama.2023.3059) — TRAILBLAZER-ALZ 2

[Shi M et al. (2021) MAbs 13(1):1954556](https://doi.org/10.1080/19420862.2021.1954556) — Fc engineering for brain delivery

[Kariolis MS et al. (2020) Nat Commun 11(1):2930](https://doi.org/10.1038/s41467-020-16458-4) — RMT approaches

[Burgess BL et al. (2022) Adv Drug Deliv Rev 180:114046](https://doi.org/10.1016/j.addr.2022.114046) — Focused ultrasound delivery

[Salloway S et al. (2024) Nature 625(7996):730-738](https://doi.org/10.1038/s41586-023-06800-3) — Donanemab long-term effects

[Huang Y et al. (2023) Alzheimers Dement 19(Suppl 5):e068234](https://doi.org/10.1002/alz.068234) — Remternetug Phase 1

External Links

[Eli Lilly Alzheimer's Pipeline](https://www.lilly.com)
[Kisunla (Donanemab) Product Information](https://kisanla.com)
[ClinicalTrials.gov](https://clinicaltrials.gov)

References

[Mintun MA et al., (2021) N Engl J Med 384(18):1691-1704 (2021)](https://doi.org/10.1056/NEJMoa2106444)

[Sims JR et al., (2023) JAMA 329(13):1108-1117 (2023)](https://doi.org/10.1001/jama.2023.3059)

[Shi M et al., (2021) MAbs 13(1):1954556 (2021)](https://doi.org/10.1080/19420862.2021.1954556)

[Kariolis MS et al., (2020) Nat Commun 11(1):2930 (2020)](https://doi.org/10.1038/s41467-020-16458-4)

[Burgess BL et al., (2022) Adv Drug Deliv Rev 180:114046 (2022)](https://doi.org/10.1016/j.addr.2022.114046)

[Salloway S et al., (2024) Nature 625(7996):730-738 (2024)](https://doi.org/10.1038/s41586-023-06800-3)

[Huang Y et al., (2023) Alzheimers Dement 19(Suppl 5):e068234 (2023)](https://doi.org/10.1002/alz.068234)

Unknown, Eli Lilly R&D presentations (2023-2024) (2023)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery](/hypothesis/h-d78123d1) — 0.52 · Target: RAB27A/LAMP2B
[Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring](/hypothesis/h-e23f05fb) — 0.42 · Target: Disease-causing mutations with integrated reporters
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Gut Barrier Permeability-α-Synuclein Axis Modulation](/hypothesis/h-6c83282d) — 0.60 · Target: CLDN1, OCLN, ZO1, MLCK
[RAB27A-dependent extracellular vesicle engineering for mitochondrial cargo delivery](/hypothesis/h-250b34ab) — 0.57 · Target: RAB27A
[Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery](/hypothesis/h-346639e8) — 0.48 · Target: TRAK1_KIF5A
[Mitochondrial SPM Synthesis Platform Engineering](/hypothesis/h-13bbfdc5) — 0.47 · Target: ALOX5

Related Analyses:

[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Mitochondrial transfer between neurons and glia](/analysis/SDA-2026-04-01-gap-20260401231108) 🔄
[Mitochondrial transfer between astrocytes and neurons](/analysis/SDA-2026-04-01-gap-v2-89432b95) 🔄

📖 View canonical wiki page →

Eli Lilly Blood-Brain Barrier Delivery Platform

Eli Lilly Blood-Brain Barrier Delivery Platform

Overview

Eli Lilly Blood-Brain Barrier Delivery Platform

Overview

Multi-Modal CNS Delivery Approach

1. Fc Engineering

2. Receptor-Mediated Transcytosis

3. Focused Ultrasound Combination

Donanemab (Kisunla) — Brain Exposure Data

Clinical Trial Results

Brain Penetration Advantages

Remternetug — Next-Generation Program

Mechanism

Clinical Status

Advantages Over Donanemab

Pipeline Programs

Alzheimer's Disease

Other CNS Indications

Focused Ultrasound Partnerships

Collaboration Approach

Potential Benefits

Comparison with Industry

BBB Delivery Approaches

Key Publications

See Also

External Links

References

Related Hypotheses